Title

AParadigm Shift: The New Novel Oral Anticoagulation Agents.

Publication/Presentation Date

7-1-2016

Abstract

Atrial fibrillation (AF) is the most common arrhythmia and represents one-third of the arrhythmia-related hospital admissions in the developed countries. Embolic strokes associated with AF are more severe and disabling. Thromboembolic stroke prevention is a major goal in treatment of AF and Warfarin has successfully served this purpose for many years. Drug-drug interaction and regular monitoring with Warfarin pose a significant challenge where health care system has limited resources; and lack of a well-structured health system, hinders regular International Normalized Ratio (INR) monitoring. Novel oral anticoagulants (NOACs) have opened up a new exciting chapter in the field of anticoagulation in non-valvular atrial fibrillation (NVAF). This review discussed the landmark trials that led to the development of NOACs and explored the potentials of these new agents with simultaneous comparison of Warfarin.

Volume

26

Issue

7

First Page

611

Last Page

619

ISSN

1681-7168

Disciplines

Medical Sciences | Medicine and Health Sciences

PubMedID

27504556

Department(s)

Department of Medicine, Cardiology Division, Department of Medicine Faculty

Document Type

Article